2010年5月1日 · Purpose: A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC). Here, we report overall survival (OS) data.

2008年5月20日 · Background: Results from the phase III AVOREN trial have shown that first-line treatment with bevacizumab (BEV; Avastin ®) + interferon-α2a (IFN) significantly improves progression-free survival (PFS) in pts with mRCC compared with IFN + placebo (median: 10.2 vs 5.4 mths, HR=0.63; p=0.0001).

2010年4月5日 · Bevacizumab is a humanized monoclonal antibody that precisely inhibits the activity of vascular endothelial growth factor (VEGF), a key mediator of tumor angiogenesis. 3 The randomized, double-blind, phase III AVOREN trial compared bevacizumab 10 mg/kg every 2 weeks plus IFN 9 MIU three times a week with IFN plus placebo in patients with ...

2010年4月5日 · Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC).

The use of bevacizumab plus IFN-α combination in mRCC is supported by the AVOREN trial. Although the primary end point of the AVOREN trial was overall survival, progression-free survival was used to evaluate efficacy and served as the basis of regulatory submission owing to the advent of targeted agents that probably resulted in the ...

2007年12月22日 · Interpretation: The combination of bevacizumab with interferon alfa as first-line treatment in patients with metastatic renal cell carcinoma results in a significant improvement in progression-free survival, compared with interferon alfa alone.

2010年4月1日 · A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC). Here, we report...

干扰素中加用Avastin (贝伐单抗)治疗晚期肾癌，比其单独使用干扰素治疗效果好，可使患者有机会多生存一倍的时间而无复发 (无进展生存)。 这一结论得自于今天在43届ASCO年会上首次公布的重要Ⅲ期AVOREN临床试验结果。 AVOREN试验结果显示，通过添加Avastin到干扰素中 (当前的晚期肾癌标准治疗方案)： 无进展生存的中位数从5.4增到10.2，几乎增加了一倍； 当添加Avastin时，肿瘤的反应性从单独使用干扰素的12.8%增加到31.4%。 Escudier教授说：“由于化疗和放疗 …

BEVLiN was designed to allow descriptive, cross-trial comparison with the BEV + IFN 9 MIU-treated favourable/intermediate Motzer score AVOREN subgroup. Primary end points are safety (specific grade [Gr] ≥3 IFN-associated adverse events [AEs]) and progression-free survival (PFS).

Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-α2a (IFN; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). We evaluated bevacizumab with low-dose IFN in mRCC to determine whether clinical benefit could be maintained with reduced toxicity.